Compare Fox Corp Class A (FOXA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Medpace Holdings Inc — how do they compare? Fox Corp Class A trades at $62.41 (market cap $25.36B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 0.91% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Medpace Holdings Inc for 14 Days on average.
| FOXA | MEDP | |
|---|---|---|
Market Cap | $25.36B | $16.82B |
Volume | 2,566,954 | 223,093 |
Sector | Media | Health |
52-Week High | $76.11 | $630.19 |
52-Week Low | $48.79 | $393.42 |
Typical Hold Time | 34 Days | 14 Days |
Enterprise Value | $28.72B | $16.44B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.57, up 1.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust 2025 results with revenue of $16.3B and net income of $2.26B, supported by solid cash flow. Analyst consensus is a Buy with a $72.00 price target, and recent news highlights the ongoing $22B Roku acquisition process and insider buying by CEO Lachlan Murdoch.
The outlook is positive given strong fundamentals and analyst support, but risks include regulatory scrutiny of the Roku deal and a projected net cash flow decline in 2026. The stock offers value with a P/E of 16.55 and growth potential, though investors must monitor deal approval and competitive pressures in media.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
